Supplied formLinear 28-residue peptide with N-terminal acetylation and free C-terminal carboxyl group
Lead time10–18 days
Representative packaging image · verify the ordered lot
Decision summary
Key benefits
Research value includes standards and reagents for innate/adaptive immune signaling, dendritic-cell and Toll-like-receptor-related studies, immune-cell assay development, and replication of indication-specific preclinical or clinical biomarker work
These applications do not establish broad immune-boosting, infection, sepsis, cancer or anti-ageing benefits.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.
Qualification data
Specifications to confirm against the released lot
CAS
62304-98-7
Formula
C129H215N33O55
Molecular weight
3108.3 g/mol
Appearance
Lot-specific lyophilized research peptide, commonly white to off-white; appearance is not a purity or sterility test
Purity
≥ 99.0% · target, verify batch COA
Storage
Follow the released-lot label and stability statement. Keep lyophilized material sealed and protected from moisture. Qualify solvent, concentration, pH, container, temperature and hold time after reconstitution; no universal seven-day hold is assigned.
Identity, purity and content are separate release questions.
Identity
Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.
Purity
Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.
Content
Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.
Stability
Follow the storage condition stated on the batch COA or label from receipt onward.
Research context
What researchers study about Thymosin Alpha 1
Thymosin alpha-1 is a linear 28-residue peptide with an acetylated N-terminus and free C-terminal carboxyl group. It was isolated and sequenced from thymosin fraction 5 and is now used as a defined synthetic research peptide. It must be distinguished from thymulin and from heterogeneous thymic extracts marketed as Thymalin.
Peptide identity and impurity methods; dendritic-cell and innate/adaptive immune models
Toll-like-receptor-related assays; immune-cell biomarker research; formulation and aggregation studies; replication of indication-specific published experiments.
Mechanism context
The question the literature is testing
Talpha1 has been associated with dendritic-cell, Toll-like-receptor and downstream immune-response modulation across experimental systems. Mechanistic effects vary with cell type, disease state and assay conditions; pleiotropic signaling observations do not establish a single receptor mechanism or universal clinical outcome.
Evidence map
Research routes and exposure context
Evidence tierApproved finished-product contextResearch areaImmune signaling researchRoutes reported in sources
No administration route applies
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.
Evidence boundaries
Compatibility, limitations and decision context
Research Use Only; not a sterile finished drug and not for human or veterinary use
FDA states that compounded Talpha1 may pose immunogenicity risks and presents peptide-impurity and API-characterization complexities, with inadequate safety information for proposed routes
Handle under the SDS and institutional risk assessment.
Interactions reported in the literature
For bench work, control endotoxin, serum proteins, cell source, activation state, cytokine background, formulation and co-treatments
No interferon, vaccine, chemotherapy, corticosteroid or peptide-combination recommendation is made.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.
Batch documentation
Thymosin Alpha 1 batch COAs
Laboratory: Manufacturer's QC laboratoryTests: HPLC purity · MS identity · endotoxin · fill amount
2 mg
5 mg
10 mg
Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.
Published COAs show recent representative batches and may not be the newest. For a quote or shipment, sales confirms the lot and sends its COA.
Third-party reports, added progressively
Previews of the first page of third-party reports are on our Quality page and on the matching product pages; sales sends the full report on request. You can also send any vial from your order to an independent laboratory of your choice. Unless agreed otherwise in writing, the buyer pays for optional testing.
Help reviewing your COA
Need help reading a batch COA or third-party report? Sales can explain the test items, specifications and how the results relate to the lot under discussion.
On every batch COA: HPLC purity · MS identity · endotoxin · fill amount · Verify LyoPep
Third-party reports for Thymosin Alpha 1
Reports from Qorix (tjqxgd.com), a third-party analytical laboratory in Tianjin, China: HPLC purity and MS identity of the sample tested.
Laboratory: Third-party laboratoryTests: HPLC purity · MS identity
5 mg
10 mg
Previews are blurred on purpose so the documents cannot be reused; third-party reports show their first page only. Sales sends the clear full version for the product and strength you ask about.
Ask for the current packet, not a generic certificate
Require N-terminal acetylation identity, exact sequence, intact mass, RP-HPLC purity with method and integration, peptide content, related substances, counterion, water and residual solvents
For immune-cell research, specify endotoxin and bioburden limits separately
Appearance or solution clarity cannot establish identity, sterility or low endotoxin.
Batch COA for the released lotHPLC purity with method contextMS identity resultEndotoxin resultFill amount (measured content per vial)SDS and handling statement
Available fills
Quote the fill and pack configuration you need
Reference SKUFillBase pack
TA22 mg10 vials
TA55 mg10 vials
TA1010 mg10 vials
Other format
Also available as a nasal spray (US stock)
10 mL nasal spray bottle
Besides lyophilized vials, Thymosin Alpha 1 is also supplied as a nasal spray solution, shipped from our US stock.
Strengths
10 mg
Bottle sizes
10 mL or 20 mL
Minimum order
10 bottles per strength and bottle size
Ships from
Our US stock
Handling
Plan storage before the parcel arrives
Follow the released-lot label and stability statement. Keep lyophilized material sealed and protected from moisture. Qualify solvent, concentration, pH, container, temperature and hold time after reconstitution; no universal seven-day hold is assigned.
State the destination and timing so receipt can be planned, then move the material into its stated storage condition on arrival.
Buyer FAQ
Terms to settle before the purchase order
Can a buyer arrange third-party testing?+
Yes. You can send any vial from your order to an independent laboratory of your choice. If you want the laboratory, specification, sampling, method and acceptance rule agreed with us before testing, sales confirms them in writing. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.
What if my own lab test shows the product is out of specification?+
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Does HPLC purity prove peptide content?+
No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.
How should material be stored after delivery?+
Move it into the storage condition stated on the batch COA or label as soon as it arrives, and record the package condition on receipt.
How are payment terms handled?+
Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.
Why must the testing laboratory understand peptide chemistry?+
Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.
Selected sources
Literature behind the research context
Identity: PubChem CID 16130571 and Goldstein et al. 1977. Human PK context: PMID 10027483. Sepsis evidence: ETASS, PMID 23327199; TESTS, PMID 39814420; and Gu et al. 2025. COVID-19 evidence: linked trials, systematic reviews and critiques. U.S. regulatory context: FDA PCAC 2024 meeting materials, vote record and current compounding safety-risk page.
01
Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide
Proceedings of the National Academy of Sciences of the United States of America (PNAS) · 1977 · peer-reviewed original research (landmark discovery paper)
How do Thymosin Alpha-1, Thymulin and Thymalin differ?+
Thymosin Alpha-1 (thymalfasin) is a defined N-acetylated 28-residue peptide. Thymulin is a distinct zinc-dependent nonapeptide, while Thymalin generally refers to a heterogeneous thymic extract rather than one molecular entity. They require different identity tests and are not interchangeable; specify the exact material at quotation.
Which analytical controls are most important for Thymosin Alpha-1?+
Confirm the N-terminal acetyl group, exact 28-residue sequence and intact mass, then review RP-HPLC purity, peptide content, related peptides, counterion, water and residual solvents. For immune-cell assays, define endotoxin and bioburden limits separately because trace endotoxin can alter the same readouts under study; a high HPLC area result does not establish low endotoxin or sterility.
